Two Sigma Advisers LP Sells 478,800 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Two Sigma Advisers LP lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 78.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,034 shares of the biotechnology company's stock after selling 478,800 shares during the quarter. Two Sigma Advisers LP owned approximately 0.13% of Sarepta Therapeutics worth $15,990,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $31,000. Nkcfo LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $43,000. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Riggs Asset Managment Co. Inc. lifted its position in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 75 shares during the period. Finally, UMB Bank n.a. boosted its stake in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 197 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares of the company's stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded up $0.83 during mid-day trading on Monday, reaching $129.00. The company's stock had a trading volume of 775,153 shares, compared to its average volume of 1,234,655. The firm's fifty day moving average price is $122.71 and its two-hundred day moving average price is $131.35. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 12-month low of $85.61 and a 12-month high of $173.25. The company has a market capitalization of $12.32 billion, a P/E ratio of 102.54 and a beta of 0.77.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a "buy" rating and a $165.00 target price on the stock. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. HC Wainwright cut their target price on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a research note on Tuesday, December 3rd. Finally, Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $175.55.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.